News

FDA issues warning about radiation therapy devices


 

Therapist preparing patient

to receive radiation

Photo by Rhoda Baer

The US Food and Drug Administration (FDA) has warned healthcare providers to stop using radiation therapy devices manufactured and sold by Multidata Systems International Corporation.

The FDA said the company has distributed at least 2 devices in the US that were never reviewed by or registered with the FDA—(1) accessories to radiation therapy devices including the Real Time Dosimetry Waterphantom System and (2) the Dual Channel Electrometer.

Since 2003, Multidata has been under a decree that prohibits the company from designing, manufacturing, processing, and distributing medical devices, among other restrictions.

However, the FDA learned that Multidata manufactured and distributed medical devices in violation of the decree, including repairing and exchanging Waterphantom devices for newer design models.

As a result, on March 3, 2016, the FDA sent a letter to Multidata ordering the firm to stop designing, manufacturing, processing, packing, repacking, labeling, installing, holding for sale, and distributing any medical device. The company has permanently ceased operations and will be dissolving.

The FDA said it doesn’t know how many devices manufactured by Multidata are in use throughout the US or if any of these devices have caused adverse events since the decree was issued.

The agency has urged healthcare providers to stop using and dispose of any devices manufactured by Multidata.

Instead, providers should use accessories to radiation therapy devices and radiation treatment planning software that have been cleared by the FDA. Registered manufacturers of such products are listed under the IYE product code in the FDA’s Registration and Listing Database.

The FDA has also recommended that providers report any adverse events related to Multidata devices. Reports can be submitted through MedWatch, the FDA’s Safety Information and Adverse Event Reporting Program.

Recommended Reading

STIM1 long-term follow-up confirms imatinib discontinuation safety
MDedge Hematology and Oncology
Single-cell findings could inform CLL treatment
MDedge Hematology and Oncology
Burden of cancer varies by cancer type, race
MDedge Hematology and Oncology
Combo produces CR/CRis in FLT3-ITD AML
MDedge Hematology and Oncology
Work reveals potential therapeutic targets in AML
MDedge Hematology and Oncology
Findings could aid treatment of resistant T-ALL
MDedge Hematology and Oncology
Proteins may be therapeutic targets for AML subtype
MDedge Hematology and Oncology
CHMP recommends conditional approval of drug for CLL
MDedge Hematology and Oncology
Combo could treat AML, other cancers
MDedge Hematology and Oncology
Doc provides perspective on CAR T-cell therapy in CLL
MDedge Hematology and Oncology